CRATOS - Evaluation of Cratos™ Branch Stent Graft System in Treatment of Descending Aorta Lesions

Inclusion Criteria: Presence of thoracic aortic pathology (Dissection, including IMH and ULP; and PAU) deemed to warrant surgical repair which requires proximal graft placement in Zone 2 Age ≥18 years at time of informed consent signature Informed Consent Form (ICF) is signed by Subject or legal representative Must have appropriate proximal aortic landing zone, defined as: Landing zone inner diameters between 23-41 mm The length of landing zone ≥15mm Landing without heavily calcified or heavily thrombosed Dissection Patients: Primary entry tear must be distal to LSA, and proximal extent of the proximal landing zone must not be dissected. For patients with prior replacement of the ascending aorta and/or aortic arch by a surgical graft, there must be at least 2 cm of landing zone proximal to the most distal anastomosis site. Must have appropriate LSA landing zone, defined as: Inner diameters of LSA 5-14 mm Minimum length of Left subclavian artery is 25 mm Target branch vessel landing zone must be in native aorta that cannot be severely tortuous , aneurysmal, dissected, heavily calcified, or heavily thrombosed. Must have appropriate distal aortic landing zone, defined as: Aortic inner diameters between 18-44 mm Landing zone cannot be heavily calcified, or heavily thrombosed. For isolated PAU, outer curvature length must be ≥ 2cm proximal to the celiac artery Landing zone in native aorta Exclusion Criteria: Concomitant disease of the ascending aorta or aneurysm of the abdominal aorta requiring repair Previous endovascular repair of the ascending aorta Infected aorta, active systemic infection Surgery within 30 days prior to enrolment with the exception of placement of vascular conduit for access . Life expectancy <1 years Myocardial infarction within 6 weeks prior to treatment Stroke within 6 weeks prior to treatment. Pregnant or breastfeeding female Patient has an active systemic infection (e.g., infection requiring treatment with parenteral anti-infective medication) that may place the patient at increased risk of endovascular infection. Degenerative connective tissue disease, e.g., Marfan's or Ehlers-Danlos Syndrome Participation in another drug or medical device study within one year of study enrolment Known history of drug abuse within one year of treatment Tortuous or stenotic iliac and/or femoral arteries preventing introducer sheath insertion and the inability to use a conduit for vascular access Planned coverage of celiac artery Allergic to contrast agents, anaesthetics and delivery materials Previous instance of Heparin Induced Thrombocytopenia type 2 (HIT-2) or known hypersensitivity to heparin Patient with a history of a hypercoagulability disorder and/or is currently in a hypercoagulability state Persistent refractory shock (systolic blood pressure <90 mm Hg) Renal failure defined as patients with an estimated Glomerular Filtration Rate (eGFR) <30 (ml/min/1.73 m2) or currently requiring dialysis Contraindications to antiplatelet drugs and anticoagulants Investigator judged that not suitable for interventional treatment.